Virtu Financial’s Ovid Therapeutics OVID Stock Holding History

Virtu Financial’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,664	Closed	-$4K	–	1918
2025 Q2	$4K	Buy	+12,664	New	+$3.82K	﹤0.01%	1358
2024 Q1	–	Sell	-24,264	Closed	-$78K	–	1907
2023 Q4	$78K	Buy	+24,264	New	+$82.9K	0.01%	1079
2023 Q2	–	Sell	-17,892	Closed	-$46K	–	1887
2023 Q1	$46K	Buy	+17,892	New	+$42.4K	﹤0.01%	1115
2022 Q4	–	Sell	-10,347	Closed	-$19K	–	2006
2022 Q3	$19K	Buy	+10,347	New	+$21.6K	﹤0.01%	1408
2021 Q1	–	Sell	-15,625	Closed	-$36K	–	1906
2020 Q4	$36K	Buy	15,625 +1,855	+13%	+$8.65K	﹤0.01%	1286
2020 Q3	$79K	Buy	+13,770	New	+$92.1K	0.01%	752
2019 Q4	$305K	Buy	73,511 +48,865	+198%	+$154K	0.03%	672
2019 Q3	$80K	Buy	+24,646	New	+$56K	0.01%	1126
2019 Q2	–	Sell	-10,121	Closed	-$18K	–	1742
2019 Q1	$18K	Buy	+10,121	New	+$25.3K	﹤0.01%	1294
2018 Q2	–	Sell	-13,433	Closed	-$95K	–	2352
2018 Q1	$95K	Buy	+13,433	New	+$109K	0.01%	1592

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Virtu Financial's OVID Position: Q3 2025 in Review

Virtu Financial sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 12,664 shares — an estimated $4K sold.

Virtu Financial first reported a position in OVID in Q1 2018 and held it in 10 quarters. The position peaked at $305K in Q4 2019. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Virtu Financial reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
Virtu Financial sold 12,664 Ovid Therapeutics shares in Q3 2025, an estimated $4K.
Virtu Financial first reported a position in Ovid Therapeutics in Q1 2018 and held it in 10 quarters.
Virtu Financial's Ovid Therapeutics position peaked at $305K in Q4 2019.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.